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OsteoblastAdipogenesis depends on growth factors controlling proliferation/differentiation of mesenchymal stem cells
(MSCs). Membrane binding and endocytosis of growth factors are often coupled to receptor activation and
downstream signaling leading to speciﬁc cellular responses. The novel adipokine tartrate-resistant acid phospha-
tase (TRAP) 5a exhibits a growth factor-like effect on MSCs and pre-adipocytes and induces hyperplastic obesity
in vivo. However its molecular interactionwith pre-adipocytes remains unknown. Therefore, this study aimed to
investigatemembrane interaction of TRAP and its endocytosis routes in pre-adipocytes. Confocal and/or electron
microscopy were used to detect TRAP in untreated or TRAP 5a/b treated pre-adipocytes under conditions that
allow or inhibit endocytosis in combination with co-staining of endocytotic vesicles. TRAP interaction with hep-
arin/heparan sulfate was veriﬁed by gel ﬁltration. It could be shown that TRAP 5a, but not 5b, binds to themem-
brane of pre-adipocyteswhere it co-localizeswith heparin-sulfate proteoglycan glypican-4. Also in vitro, TRAP 5a
exhibited afﬁnity for both heparin and heparan sulfate with heparin inhibiting its enzyme activity. Upon caveo-
lae-mediated endocytosis of saturating levels of TRAP 5a, TRAP 5a co-localized intracellularlywith glypican-4 and
late endosomal marker Rab-7 positive vesicles. The protein was also located inmultivesicular bodies (MVBs) but
did not co-localize with lysosomal marker LAMP-1. TRAP 5a endocytosis was also detectable in pre-osteoblasts,
but not ﬁbroblasts, embryonicMSCs ormature adipocytes. These results indicate that TRAP 5a exhibits binding to
cell surface, endocytosis and afﬁnity to glucosaminoglycans (GAGs) in pre-adipocyte and pre-osteoblast lineage
cells in a manner similar to other heparin-binding growth factors.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Recently, the heparin-binding [1–3]metalloprotein tartrate resistant
acid phosphatase (TRAP; EC 3.1.3.2)was shown to increase proliferation
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ights reserved.[4] and osteoblasts [5–9], similar to what has previously been reported
for hematopoietic stem cells [10].
In vivo, TRAP overexpressing mice develop insulin sensitive hyper-
plastic obesity [4] and increased cortical bone mass and turnover [5,11].
In humans, TRAP is secreted from adipose tissue where its secretion cor-
relates to cell number, cell size and secretion of pro-inﬂammatory cyto-
kines [12]. Moreover, TRAP is elevated in obese vs. lean human adipose
tissue [4]. TRAP exists as two isoforms, 5a and 5b, where 5a is a mono-
meric protein [4,13] suggested to exhibit growth factor activity in MSCs
and pre-adipocytes [4]. Proteolytic processing of TRAP 5a in an exposed
repressive loop domain [14] interacting with the active center, results
in TRAP 5b, a dimeric protein with an exposed active site held together
by a di-sulﬁde bond. This isoform does not display growth factor activity
in MSCs and pre-adipocytes [4], but possesses high phosphatase activity
and has been implicated in cell migration [15]. Based on these data,
we hypothesized that different cellular functions of TRAP are isoform-
speciﬁc. Still, the molecular mechanisms behind the tentative growth
factor activity of TRAP 5a, including surface binding and endocytosis,
remain elusive.
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or in combination with co-receptors e.g. ﬁbroblast growth factor (FGF)
binding to heparan sulfate (HS) containing proteoglycans (PG) [16].
TRAP is detected on the osteoblast surface upon exogenous exposure
[17]. Additionally, it has been shown that TRAP binds heparin in vitro
[1–3] and can interact with the membrane glycosylphosphatidylinositol
(GPI)-anchored PG glypican-4 in bone [18]. Following ligand–receptor
cell surface interaction, endocytosis of receptor–ligand complex displays
pleiotropic effects on cells and can be regarded as a master organizer
of signaling circuits [19]. TRAP has been shown to be endocytosed in a
dose dependent manner in osteoblasts [17,20]. No studies have previ-
ously addressed the question of intracellular sorting of endocytosed
TRAP, however it is known that endogenously expressed TRAP is locat-
ed intracellularly in lysosomes in both macrophages [21] and osteo-
blasts [22] and in late endosomal/early lysosomal Rab7-positive
vesicles, as well as vesicles containing major histocompatibility com-
plex (MHC) class II and phagocytosed bacteria in macrophages [23].
In light of previous studies hypothesizing growth factor activity of
TRAP 5a along with binding and endocytosis of TRAP in cells of MSC
lineage, the aim of this study was to evaluate if TRAP 5a binds to and
is endocytosed by adipocyte lineage cells. Additionally, the localization
of TRAP 5a in endosomal/lysosomal compartments after endocytosis
was investigated. Lastly, other cell types of theMSC lineage were evalu-
ated for their ability to endocytose TRAP 5a.2. Materials and methods
2.1. Cell lines
The 3T3-L1murine pre-adipocyte cell linewas a kind gift from Peter
Arner, Department of Medicine, Karolinska Institutet; the C3H10 T1/2
murine mesenchymal stem cell line was kindly provided by Yan Li,
ClinTec, Karolinska Institutet; 3T3-E1 clone 14 murine pre-osteoblasts
and murine NIH-3T3 ﬁbroblasts were purchased from the American
Type Culture Collection (ATCC; Borås, Sweden).2.2. Cell culture
3T3-L1 cells were grown in DMEM-F12 media supplemented with
10% donor bovine serum, 10,000 U/l penicillin and 10 g/l streptomycin
(all from Life Technologies, Stockholm, Sweden) and 0.9 g/l D-glucose
(VWR International AB, Stockholm, Sweden). C3H10 T1/2 cells and
3T3-E1 clone 14 were grown in alpha-MEM media supplemented
with 10% fetal bovine serum, 2 mM glucose, 10,000 U/l penicillin and
10 g/l streptomycin (all from Life Technologies). NIH-3T3 cells were
cultured in MEM media with 10% heat inactivated fetal bovine serum,
10,000 U/l penicillin and 10 g/l streptomycin (all from Life Technolo-
gies). All cells were incubated at 37 °C with 5% CO2 and grown until
approximately 80% conﬂuent.2.3. Production and proteolytic processing of recombinant TRAP
Recombinant full-length human his-tagged TRAP 5a referred to as
his-TRAP was produced in insect cells and puriﬁed using Ni-beads
(Genscript, Piscataway, NJ). Human non-tagged TRAP 5a referred to as
TRAP 5amedia, also produced in insect cells (Genscript) was usedwith-
out puriﬁcation after veriﬁcation by Western blot to mainly contain
TRAP 5a (Supplementary Fig. 1S). Recombinant rat TRAP 5a was pro-
duced and puriﬁed as previously described [24] and recombinant rat
TRAP 5b was generated by proteolytic cleavage of recombinant rat
TRAP 5a by cathepsin K as previously described [4]. Conditioned
media containing exclusively the TRAP 5a isoform was produced from
stably transfectedMDA-MB-231 breast cancer cells as described in [25].2.4. Production of antibodies
Antibodies against total rat TRAP, thus recognizing both TRAP 5a and
5b,were raised by immunization of NewZealand rabbits as described in
[26]. A monoclonal antibody against human TRAP 5a was obtained by
fusing spleen cells from a mouse immunized with human his-TRAP 5a
(Mabtech AB, Nacka Strand, Sweden). Speciﬁcity of the different TRAP
antibodies for TRAP isoforms 5a and 5b was analyzed by Western blot
as described below.
2.5. Western blot
Human his-TRAP 5a, TRAP 5a media and recombinant rat TRAP 5b
were mixed with Laemmli Sample Buffer (BIO-RAD, Hercules, CA) and
run on a Mini-PROTEAN®TGX™ precast gel (BIO-RAD) according to
the manufacturer's instructions. The proteins were transferred to
PVDF membrane (BIO-RAD) using the Trans-Blot turbo transfer system
and Trans-Blot turbo mini PVDF packs (BIO-RAD) according to the
manufacturer's instructions. After transfer, the membranes were
blocked in 1% bovine serum albumin (BSA; Sigma-Aldrich, Stockholm,
Sweden) inTBST (25 mMTris pH 7.4, 150 mMNaCl, 0.1%Tween-20)over-
night and incubated with rabbit anti-rat total TRAP or mouse anti-human
TRAP 5a, dilution 1:1500 and 0.68 μg/ml respectively in TBST, for 1 h at
roomtemperature.Membraneswerewashed2 ∗ 10 min inTBST and incu-
bated with IRDye 680RD goat anti-rabbit IgG or IRDye 800CW goat anti-
mouse IgG (both from LI-COR Biosciences Ltd, Cambridge, UK) according
to the manufacturer's instructions, washed twice in TBST and visualized
and analyzed using the Odyssey CLx Imager (LI-COR Biosciences Ltd) and
Image Studio software (LI-COR Biosciences Ltd).
2.6. Cell surface binding of TRAP
Mesenchymal stem cells (MSC; C3H10 1/2), pre-adipocytes (3T3-
L1) or mature adipocytes (differentiated 3T3-L1) were treated with
100 nM recombinant human his-TRAP 5a, 100 nM recombinant
human TRAP 5a media, conditioned media containing TRAP 5a from
TRAP-overexpressing MDA-MB 231 breast cancer cells [30] or 100 nM
or 200 nM recombinant rat TRAP 5a/5b diluted in DMEM-F12 media
for 1 h at 4 °C. Directly after incubation, cells were washed with
serum-free media (according to section ‘Cell culture’) for 5 min and
ﬁxed with 4% phosphate buffered saline (PBS) buffered formalin
(Solveco, Rosersberg, Sweden) for 10 min at room temperature or
acetone for 10 min at−20 °C. TRAP 5a bound to cell surface was then
detected as described under ‘Immunocytochemistry’.
2.7. Immunocytochemistry
Fixed cells were washed in TBST (25 mMTris pH 7.4, 150 mMNaCl,
0.1% Tween-20) for 5 min. After washing, cells previously TRAP treated
at 4 °C and ﬁxed in 4% PBS buffered formalin (Solveco), were incubated
in 1% BSA (Sigma-Aldrich) diluted in TBST for 20 min at room tempera-
ture to block non-speciﬁc binding while cells previously treated with
TRAP at 37 °C and ﬁxed in 4% PBS buffered formalin (Solveco) were
permeabilized using 0.1% Triton X-100 (Sigma-Aldrich) in TBST for
10 min at room temperature and then blocked as above. After blocking,
cells were incubated with rabbit anti-rat total TRAP diluted 1:200 in
TBST or 3.4 μg/ml mouse anti-human TRAP 5a in DMEM media (Life
technologies) at 4 °C overnight. Cells were washed twice in TBST for
5 min and incubated with goat anti-rabbit Alexa 488 diluted 1:100 or
goat anti-mouse or anti-rabbit Alexa 568 diluted 1:250 (both from Life
technologies) in TBST for 1 h, washed twice in TBST and stained with
Hoechst (Life technologies) diluted 1:7500 in TBST for 3 min. Finally,
cells were washed and mounted using Dako's ﬂuorescent mounting
media (DAKO, Åhus, Denmark). Samples were visualized using either
a Leica DM IRB light microscope (Leica Microsystems, Kista, Sweden)
equipped with OpenLab (PerkinElmer, Upplands Väsby, Sweden)
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(Nikon, Sweden, Stockholm) software.
2.8. Quantiﬁcation of TRAP staining on pre-adipocyte membrane
For quantiﬁcation of TRAP positive spot like staining, i.e. TRAP clus-
ters on pre-adipocyte cell membrane, pictures of ﬁve cells each from
untreated, TRAP 5a or TRAP 5b treated 3T3-L1 cells at 4 °C were ana-
lyzed using NIS-elements software (Nikon). Data on the area of each
cell were calculated using the Volocity Demo software (PerkinElmer).
For cluster quantiﬁcation, threshold of cluster dimension and intensity
was set by positive control staining of cells treated with TRAP 5a and
clusters were quantiﬁed with NIS-elements (Nikon). The cluster num-
ber in each cell was divided to the total area of the cell and the value
was converted to spots/mm2. Results were expressed as mean value of
spots/mm2 of ﬁve cells ± standard deviation (SD) and statistical analy-
sis was performed using Kruskal–Wallis followed by Mann–Whitney
test.
2.9. Electron and immunoelectron microscopy
Electron microscopy and immunoelectron microscopy were per-
formed at the Electron microscopy unit (EMil) at Karolinska Institutet
(Stockholm, Sweden). Approximately 106 3T3-L1 pre-adipocytes were
washed in serum-free DMEM-F12 media for 5 min. After washing,
cells were incubated with 100 nM recombinant human TRAP 5a
media orwith serum freemedia at 4 °C or 37 °C for 1 h. After incubation
cells were washed in serum free media twice, as described above. Cells
were then ﬁxed in 3% paraformaldehyde and 0.1% glutaraldehyde in
0.1 M phosphate buffer. Cells were washed and centrifuged to a pellet
and embedded in 10% gelatin. Specimens were then dehydrated by
stepwise increased concentration of methanol and in each step, gradu-
ally lowering the temperature down to −40 °C in a Leica EMAFS
(Leica microsystem) and embedded in Lowicryl HM23 (Polysciences,
Warrington, PA) at−40 °C and polymerized by360 nmUV-light. Ultra-
thin sections were cut at room temperature and placed on carbon
coated formvar nickel grids.
Immunolabelling procedure was performed as follows: grids were
placeddirectly ondrops of 2%BSA (fractionV; Sigma-Aldrich) and2%gel-
atin (IGSS quality, Amersham Biosciences UK limited, Buckinghamshire,
UK) in 0.1 M phosphate buffer to block non-speciﬁc binding. Sections
were then incubated with rabbit anti-rat total TRAP diluted 1:200 in
0.1 M phosphate buffer containing 0.1% BSA and 0.1% gelatin over
night in a humidiﬁed chamber at room temperature. The sections
were thoroughly washed in the same buffer and bound antibodies
were detected with protein A coated with 10 nm gold (Biocell,
BBInternational, Cardiff, England) in a ﬁnal dilution of 1:100. Sections
were rinsed in buffer and ﬁxed in 2% glutaraldehyde and contrasted
with 4% uranyl acetate followed by lead citrate and examined in a
Tecnai G2 Bio TWIN (FEI Company, Eindhoven, The Netherlands) at
100 kV. Digital images were taken by a Veleta camera (Soft Imaging
System GmbH, Műnster, Germany).
2.10. Concentration-dependent binding of TRAP
3T3-L1 cells were cultured to 80% conﬂuence, trypsinized and
pelleted by centrifugation. Cells were washed in serum free media and
incubated with 200 nM, 100 nM, 50 nM, 5 nM, 1 nM and 0.1 nM
TRAP 5a media diluted in serum free DMEM-F12 media (Life Technolo-
gies) at 4 °C to inhibit endocytosis or at 37 °C to allow endocytosis, for
1 h. After incubation, cells were washed in serum free DMEM-F12
media (Life Technologies) twice for 5 min and ﬁxed in acetone for
10 min at−20 °C. After ﬁxation cells were blocked in 1% BSA in TBST
(25 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween-20) for at least
20 min and then incubated with rabbit anti-rat total-TRAP diluted
1:200 in TBST overnight at 4 °C. After incubation cells were washedtwice for 5 min in TBST and incubated with goat anti-rabbit Alexa 488
(Life technologies) diluted 1:500 for 1 h at room temperature and
washed once in TBST and once in PBS. Samples were analyzed by ﬂow
cytometry using FACS Caliber (BD Biosciences, Bedford, MA) equipped
with FlowJo 7 (Treestar Inc., Ashland, OR).
2.11. TRAP enzyme activity measurement in the presence or absence of
heparin or heparan sulfate
For heparin study, 2 ng of human or rat TRAP 5a in 0.15 M KCl and
0.1% TritonX-100 (Sigma-Aldrich)were incubatedwith heparin sodium
salt from porcine intestinal mucosa (Sigma-Aldrich) in concentration
range of 0.1–2.0 μg/ml. The mixture was incubated for 20 min at room
temperature and TRAP enzyme activity was measured as previously
described [3].
For heparan sulfate and TRAP 5a studies, 10 ng of recombinant rat
TRAP 5a in 0.15 M KCl and 0.1% Triton X-100 (Sigma-Aldrich) were
incubated with heparan sulfate sodium salt from bovine kidney
(Sigma-Aldrich) in concentration range of 6.25–500 μg/ml. Themixture
was incubated for 30 min at 37 °C and TRAP enzyme activity was mea-
sured as previously described [3].
2.12. Gel ﬁltration chromatography of TRAP and glycosaminoglycan
(GAG) complexes
10 μg of recombinant rat TRAP 5a was incubated with ±100 μg of
heparin (Sigma-Aldrich) or HS (Sigma-Aldrich) in 100 μl of 0.15 M
KCl + 0.1% Triton X-100 for 20 min at room temperature. Thereafter,
recombinant rat TRAP 5a or recombinant rat TRAP 5a + heparin or HS
was subjected to a Superdex-75 column (GE Healthcare, Uppsala,
Sweden), equilibrated in 10 mM Tris pH 7.5, 0.1 M KCl, 0.05% Triton
X-100, attached to ÄKTA Puriﬁer 10 (GE Healthcare). The chromatogra-
phy was run using 120 ml 10 mM Tris pH 7.5, 0.1 M KCl, 0.05% Triton
X-100 at 1 ml/min and 1.5 ml fractions were collected. Presence of
TRAP in the gel ﬁltration fractions was evaluated by measuring TRAP
enzyme activity as previously described [3].
2.13. Co-localization of TRAP 5a and glypican-4, clathrin, caveolin-1 and
endocytic/lysosomal markers Rab-7 and LAMP-1
For co-localization studies, cells were treated with TRAP 5a as indi-
cated under section ‘Endocytosis of TRAP’ and stained for TRAP as indi-
cated under section ‘Immunocytochemistry’ with the following
adjustments; all antibodies except anti-TRAP antibodies were pur-
chased from Abcam, Cambridge, UK. For TRAP 5a and glypican-4 co-
staining, cells treated with TRAP 5a as indicated under section ‘Cell
surface binding of TRAP’ and ‘Endocytosis of TRAP’, were ﬁxed and
permeabilized using acetone for 10 min at−20 °C and then incubated
with rabbit anti-rat total TRAP diluted 1:200 in TBST and mouse anti-
human glypican-4 (Abcam) 1:200 in TBST. For TRAP/caveolin-1 co-
staining, cells were ﬁxed in acetone as described above and then incu-
bated with 3.4 μg/ml mouse anti-human TRAP 5a (Mabtech AB) and
rabbit anti-mouse caveolin-1 diluted 1:1000 in DMEMmedia (Life tech-
nologies). For TRAP/clathrin staining cells were ﬁxed in acetone as
described above and then incubated with 3.4 μg/ml mouse anti-
human TRAP 5a (Mabtech AB) and rabbit anti-human clathrin diluted
1:100 in DMEMmedia (Life technologies). For TRAP/Rab-7 co-staining
cells were ﬁxed in formalin and permeabilized using 0.25 M glycine
(Sigma-Aldrich) for 1 h. Primary antibodies were rabbit anti-rat total
TRAP diluted 1:200 in TBST and mouse anti-human Rab-7 diluted
1:2000 in TBST. For TRAP/LAMP-1 co-staining cells were ﬁxed and
permeabilized using acetone and primary antibodies were rat anti-
mouse LAMP-1 diluted 1:1000 in TBST and rabbit anti-rat total TRAP
diluted 1:200 in TBST. All primary antibodies were incubated at 4 °C
overnight. Secondary antibodies were goat anti-rabbit Alexa 568 (Life
technologies), goat anti-mouse Alexa 488 (Life technologies) and goat
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respectively in TBST. Analysis was done using 1AR+ confocal system
equippedwithNIS-elements software (Nikon). Co-localization informa-
tion was calculated using Volocity Demo software (PerkinElmer). For
co-localization analysis, threshold was set by control staining of cells
not treated with TRAP 5a. For each staining ﬁve images were analyzed
for co-localization and Pearson's global correlation together with the
overlap coefﬁcients for each channel (M1 for goat anti-rabbit Alexa
488 or goat anti-rat Alexa 488 and M2 for goat anti-rabbit Alexa 568)
was generated and presented as amean value of coefﬁcient ± standard
deviation (SD).2.14. Endocytosis of TRAP
For endocytosis, MSCs (C3H10 T1/2), pre-adipocytes (3T3-L1),
pre-osteoblasts (3T3-E1 clone 14) and ﬁbroblasts (NIH-3 T3) were
treated with 100 nM recombinant human his-TRAP 5a or TRAP 5a
media in DMEM-F12 media (Life Technologies) for 1 h at 37 °C.
Directly after incubation, cells were washed with serum-free media
(according to section ‘Cell culture’) for 5 min and ﬁxed with 4%
PBS buffered formalin (Solveco) for 10 min at room temperature.
Endocytosed TRAP 5a was then detected as described under
‘Immunocytochemistry’.
To study the endocytic pathway of TRAP 5a, pre-adipocytes (3T3-L1)
or pre-osteoblasts (3T3-E1 clone 14) were incubated with ±100 μM of
dynamin inhibitor Dynasore [27] (Sigma-Aldrich), 100 μM, 200 μM,
500 μM and 800 μM of the caveolae/tyrosine kinase inhibitor Genistein
[28] (Sigma-Aldrich) or 250 μM, 500 μM, 750 μM and 1 mM of the
clathrin inhibitor Monodansylcadaverine [29] (MDC; Sigma-Aldrich)
diluted in serum free media for 1 h at 37 °C. After washing with
serum free media for 5 min, cells were incubated with respective in-
hibitor and 100 nM recombinant human his-TRAP 5a (Genscript),
diluted in serum free media for 1 h at 37 °C. After washing with
serum free media 3 times for 5 min, staining for TRAP 5a was per-
formed as described under ‘Immunocytochemistry’ with the excep-
tion that the cells were incubated with secondary antibody goat
anti-rabbit Alexa 568 1:250 (Life technologies) overnight at 4 °C.
To study TRAP 5a uptake through the caveolae pathway, cells were
also treated with TRAP as described above and co-stained for TRAP
and clathrin or TRAP and caveolin-1. For co-staining cells were treat-
ed as described under section ‘Co-localization of TRAP 5a and
glypican-4, clathrin, caveolin-1 and endocytic/lysosomal markers
Rab-7 and LAMP-1’.2.15. Differentiation of 3T3-L1 pre-adipocytes to adipocytes
Cells were seeded at 10,000 cells/well in black/clear 96-well plates
(BD AB, Stockholm, Sweden) and were allowed to grow to conﬂuence
(day −2), when conditioned media containing exclusively TRAP 5a
[25] was added. Two days post-conﬂuence (day 0), media was changed
to differentiation media [DMEM-F12 (Life Technologies), 10% fetal
bovine serum (Life Technologies), 0.9 g/l D-glucose (VWR International
AB, Stockholm, Sweden), 10 U/ml penicillin and 10 mg/ml streptomy-
cin (Life Technologies), bovine insulin 10 μg/ml (Sigma-Aldrich),
dexamethasone 1 μM (Sigma-Aldrich), 3-isobutyl-1-methylxanthine
(IBMX) (Sigma-Aldrich) 0.2 mM ± rosiglitazone 10 μM (Cayman
Chemical Company, Ann Arbor, Michigan)] ± conditioned media
containing exclusively TRAP 5a [25]. After 48 h cells were washed
once in serum free media and ﬁxed in 4% PBS buffered formalin for
10 min. After ﬁxation cells were stained for TRAP 5a according to the
section ‘Immunocytochemistry’. For staining of the lipid droplets, cells
were incubated with 2.1 mg/ml Oil Red O (Sigma-Aldrich) in 60%
isopropanol (Merck, Darmstadt, Germany) for 10 min at room temper-
ature and washed with water.3. Results
3.1. TRAP antibody speciﬁcity for TRAP 5a and b
The species and isoform speciﬁcity of antibodies against TRAP were
analyzed by Western blot. Rabbit anti-rat total TRAP detected, as
expected, both recombinant human and rat TRAP 5a and b whereas
mouse anti-human TRAP 5a antibody only detected recombinant
human but not recombinant rat TRAP 5a (Fig. 1S).
3.2. TRAP 5a binds to the plasma membrane and is endocytosed in pre-
adipocytes, but not mature lipid containing adipocytes, in a concentration-
dependent fashion
To investigate how TRAP binds to pre-adipocytes, 3T3-L1 mouse
pre-adipocytes were incubated with recombinant human TRAP 5a
media, recombinant human his-TRAP 5a or recombinant rat TRAP 5a
or b at 4 °C to blunt endocytosis. Immunocytochemical detection,
using confocal microscopy, of TRAP 5a revealed that untreated pre-
adipocytes displayed no detectable TRAP 5a staining (Fig. 1A; arrow)
while a spotted pattern was present on the plasma membrane of TRAP
5a treated pre-adipocytes (Fig. 1B; arrow, Supplementary Fig. 2S A–B;
arrows) resembling the pattern of clustered receptors. In contrast,
pre-adipocytes treated with TRAP 5b did not show any detectable
TRAP staining (Fig. 1C arrow). Quantiﬁcation of spot like TRAP stained
clusters on the surface of TRAP 5a or b treated pre-adipocytes compared
with untreated pre-adipocytes showed a signiﬁcant increase in the
number of TRAP stained clusters in TRAP 5a treated, but not TRAP 5b
treated pre-adipocytes (Fig. 1D). Electron microscopy analysis of 3T3-
L1 pre-adipocytes incubated with recombinant human TRAP 5a media
followed by immunohistochemical TRAP staining conﬁrmed that on
the surface, TRAP 5awasmainly accumulated in clusters and not evenly
spread (Fig. 1E–F magniﬁcations; Supplementary Fig. 2S C–D) while
no TRAP positive clusters were observed on the surface of untreated
cells (Fig. 1G). Intracellularly, TRAP staining was found, using electron
microscopy, in endocytosed vesicles (Fig. 1H, Supplementary Fig. 2S
E–F). This pattern was conﬁrmed using confocal microscopy analysis
of pre-adipocytes treated with TRAP 5a at 37 °C where endocytosis is
allowed (Fig. 1I arrows).
To investigate if also mature lipid containing adipocytes possess the
ability for TRAP 5a binding and endocytosis, a population of mixed 3T3-
L1 pre-adipocytes and mature lipid containing 3T3-L1 adipocytes was
treated with conditioned media containing TRAP 5a from TRAP-
overexpressingMDA-MB 231 breast cancer cells [30] at 37 °C, followed
by staining for TRAP. Results showed that TRAP 5a staining was present
only in pre-adipocytes (Fig. 1J open arrows), while undetectable in
mature lipid containing adipocytes, deﬁned as Oil Red O positive cells
(Fig. 1J closed arrows), indicating that the ability to bind and endocytose
TRAP 5a is lost during differentiation from pre-adipocyte to mature
lipid-containing adipocytes. 3T3-L1 pre-adipocytes and mature lipid
containing adipocytes that were allowed to differentiate in the absence
of TRAP 5a showed no detectable TRAP staining (Fig. 1K, closed arrows
mature adipocytes and pre-adipocytes open arrows), a pattern similar
to cells used as control stained only for Oil Red O lipid i.e. mature lipid
containing adipocytes (Fig. 1L).
Concentration dependence of TRAP 5amembrane binding and endo-
cytosis in pre-adipocytes, was investigated using FACS analysis. 3T3-L1
pre-adipocytes were treated with 0.1 to 200 nM recombinant human
TRAP 5amedia at 4 °C to prevent endocytosis or at 37 °Cwhere endocy-
tosis is proceeding. FACS analysis showed a TRAP 5a concentration
dependent ﬂuorescent signal that followed a sigmoidal ﬁt up to approx.
100 nM for both membrane binding (pre-adipocytes treated at 4 °C;
R2 = 0.60233; Fig. 2A) and endocytosis (pre-adipocytes treated at
37 °C; R2 = 0.5158; Fig. 2B). At concentrations above 100 nM, the ﬂuo-
rescent signal did not increase in eithermembrane binding or endocyto-
sis indicating that the binding was saturated.
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Fig. 1. TRAP 5a but not 5b binds to the membrane of pre-adipocytes. A) Untreated 3T3-L1 pre-adipocytes stained for TRAP using rabbit anti-rat total TRAP (red) at 4 °C. Arrow points at
unstainedmembrane. B) 3T3-L1 pre-adipocytes treated with 100 nM recombinant non-tagged human TRAP 5amedia at 4 °C. TRAP stainingwas detected using rabbit anti-rat total TRAP
(red). Arrow points at TRAP stained clusters in the membrane. C) 3T3-L1 pre-adipocytes incubated with 100 nM recombinant rat TRAP 5b 4 °C. TRAP staining was detected using rabbit
anti-rat total TRAP (red). Arrow points at unstained membrane. D) Quantiﬁcation of TRAP stained clusters in untreated, 100 nM recombinant human TRAP 5a media or 100 nM recom-
binant rat TRAP 5b treated 3T3-L1 pre-adipocytes at 4 °C. Statistical analysis was performed onmean values (spots/mm2) of ﬁve samples per treatment using Kruskal–Wallis followed by
Mann–Whitney U test. E–F) 3T3-L1 pre-adipocytes incubated with 100 nM recombinant human TRAP 5a media at 37 °C at E and 4 °C at F. TRAP staining on the membrane surface was
detected by electron microscopy using rabbit anti-rat total TRAP. G) Control; untreated 3T3-L1 pre-adipocytes. TRAP staining was detected by electron microscopy using rabbit anti-rat
total TRAP. H) 3T3-L1 pre-adipocytes incubated with 100 nM recombinant human TRAP 5a media at 37 °C. Intracellular TRAP staining was detected by electron microscopy using rabbit
anti-total TRAP. I) 3T3-L1 cells incubated with 100 nM recombinant human TRAP 5a media at 37 °C and stained for TRAP 5a using rabbit anti-rat total TRAP (red). Arrows point at TRAP
stained vesicles in the cytoplasm. J) 3T3-L1 pre-adipocytes and mature adipocytes incubated with conditioned media containing TRAP 5a on day 2 of differentiation and stained with Oil
RedO (red) for lipids and rabbit anti-rat total TRAP (green). Open arrowspoint at pre-adipocyteswith TRAP 5a stained intracellular vesicles. Closed arrowspoint atmature-adipocytes. The
scale bar on images A–C and I is 10 μm. The scale bar on images G–H is 200 nm. The scale bar on images J–I is 200 μm. CM = cell membrane, V = vesicles, P = protrusions.
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Fig. 2. TRAP 5a binds to themembrane of pre-adipocytes and is endocytosed in a concen-
tration dependent manner. Flow cytometry of cells treated with 0.1–200 nM of TRAP 5a
media and stained for TRAP using rabbit anti-rat total TRAP. A) Cells treated with TRAP
5a at 4 °C. B) Cells treated with TRAP 5a at 37 °C. Values are expressed as fold change of
mean intensity of untreated cells. Statistical analysis was performed using Kruskal–Wallis
followed byMannWhitney U test. SD = standard deviation, * = p ≤ 0.05. The R2 value is
calculated by sigmoid ﬁt. For experiment on 2A n = 3 and on 2B n = 4.
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with the membrane bound proteoglycan glypican-4 in pre-adipocytes
It is common for growth factors to bind co-receptors such as heparan
sulfate proteoglycans (HSPG) in order to fully induce an activating
response in the target cell [31]. TRAP has been shown to interact with
heparin [1–3], and therefore it was further investigated if TRAP 5a
interacts with heparin as well as HS. When recombinant rat TRAP 5a
was incubated with HS or heparin and subjected to gel ﬁltration chro-
matography, elution of TRAP 5a alone peaked at approximately 75 ml
while elution of TRAP 5a + HS or TRAP 5a + heparin eluted at 60 and
50 ml, respectively (Fig. 3A), indicating that TRAP 5a forms a complex
with HS and heparin. In respect to TRAP enzyme activity, heparin
inhibited both rat and human TRAP 5a activity by about ~20 and 40%
respectively (Fig. 3B) while HS did not signiﬁcantly inhibit TRAP 5a
enzyme activity (Fig. 3C).
In vivo, HS is part ofmembrane bound or extracellularmatrix (ECM)
proteoglycans which often function as co-receptors for growth factors.
It has been suggested that TRAPmight interact with themembrane pro-
teoglycan glypican-4 [18], therefore it was investigated whether TRAP
5a and glypican-4 are co-localized in 3T3-L1 pre-adipocytes at both
4 °C and 37 °C. The immunocytochemical analysis showed a partial
co-localization between TRAP 5a and glypican-4 at 4 °C (Pearson's
coefﬁcient = 0.63, M1 = 0.39, M2 = 0.7) when endocytosis is
inhibited mainly on the edges of the cell membrane and on cellprotrusions (Fig. 3D upper panel merged; arrows). The low M1 value
suggests that glypican-4 is localized without the presence of TRAP 5a
to a large extent while, as observed from the higher M2 value, most of
the TRAP 5a clusters are co-localized with glypican-4. Intracellular co-
localization of TRAP 5a and glypican-4 after endocytosis showed a
high co-localization with Pearson's coefﬁcient of 0.81 (Fig. 3D lower
panel merged; arrows). Moreover, TRAP 5a exhibited complete co-
localization with glypican-4 (M1 = 0.9; Fig. 3D) while glypican-4 ex-
hibited high, but not complete, co-localization with TRAP 5a
(M2 = 0.7; Fig. 3D). No staining was observed in cells in the absence
of primary or secondary antibodies or cells only stained with Hoechst
(Supplementary Fig. 3S). Additionally, in order to evaluate that the
TRAP staining was not due to cross-reactivity of the TRAP antibodies,
TRAP untreated 3T3-L1 pre-adipocytes were stained for both TRAP
and glypican-4 and no TRAP staining was observed in these controls
(Supplementary Fig. 4S).
3.4. Endocytosis of TRAP 5a in pre-adipocytes is caveolae-mediated
Binding of ligands to cell surface receptors and induction of signal
responses in cells are often associated with endocytosis of the recep-
tor–ligand complex [32]. Therefore the endocytosis route of TRAP 5a
was studied in 3T3-L1 pre-adipocytes.
To study if TRAP 5a endocytosis is dependent on dynamin, 3T3-L1
pre-adipocytes were treated with ±100 nM recombinant human his-
TRAP 5a in the absence or presence of dynamin inhibitor Dynasore. In
the absence of inhibitor, endocytosis of TRAP 5awas observed as a spot-
ted pattern in the cytoplasm (Fig. 4A left image). However, in the pres-
ence of Dynasore, no TRAP 5a staining was observed in the cytoplasm
(Fig. 4A middle image; arrows), indicating that endocytosis of TRAP 5a
is dependent on dynamin, i.e. clathrin- or caveolae-mediated.
To distinguish between clathrin and caveolae-mediated uptake,
TRAP 5a endocytosis in the presence of endocytosis inhibitors
Monodansylcadaverin (MDC) and Genistein (GS) as well as co-
staining of TRAP 5a and clathrin/caveolin-1 were analyzed. As
shown in Fig. 4B, treatment of 3T3-L1 pre-adipocytes with the
clathrin-dependent endocytosis inhibitor MDC in the range of
500 μM to 750 μMhad little or no effect on the amount of TRAP 5a pos-
itive vesicles. Additionally, when TRAP 5a treated cells were co-stained
for TRAP and clathrin, almost no co-localization was observed (Fig. 4C;
Pearson's co-efﬁcient = 0.003). The overlap co-efﬁcient for TRAP to
clathrinwas however rather high (Fig. 4C;M1 = 0.7)while the overlap
co-efﬁcient for clathrin to TRAP was very low (Fig. 4C; M2 = 0.13). In
contrast, when the caveolae-mediated endocytosis inhibitor GS was
introduced to 3T3-L1 pre-adipocytes before and together with addition
of 100 nM recombinant human his-TRAP 5a, a loss of TRAP stainingwas
observed with increasing concentrations of GS (Fig. 4D; arrows). Addi-
tionally, recombinant human his-TRAP 5a co-stained with the caveolae
protein caveolin-1 in intracellular vesicles in 3T3-L1 pre-adipocytes
(Pearson's coefﬁcient = 0.5, M1 = 0.46, M2 = 0.76; Fig. 4C). These
data suggest that at high concentrations (100 nM), TRAP 5a is
endocytosed through the caveolae endocytosis pathway. In control
cells treated with only MDC or GS no TRAP staining was observed in
the cytoplasm (Fig. 4B and D). No staining was observed in cells in the
absence of primary or secondary antibodies or cells only stained with
Hoechst (Supplementary Fig. 3S). Additionally in order to evaluate
that the TRAP staining was not due to cross-reactivity of the TRAP
antibodies, TRAP untreated 3T3-L1 pre-adipocytes were stained for
both TRAP and clathrin/caveolin-1 and no TRAP staining was observed
in these controls (Supplementary Fig. 4S).
3.5. Intracellular localization of endocytosed TRAP 5a in pre-adipocytes
Intracellular localization of TRAP in the endocytic pathway was
investigated using markers for different endocytic compartments in
confocal microscopy, and TRAP staining using electron microscopy.
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Fig. 3. TRAP 5a interacts with heparin and heparan sulfate in vitro and is co-localized with glypican-4 in vesicles of pre-adipocytes. A) Gel ﬁltration chromatography of recombinant rat
TRAP 5a, TRAP 5a + heparan sulfate and TRAP 5a + heparin. B) Recombinant rat and human TRAP 5a enzyme activity inhibition after incubation with various concentrations of heparin.
The graph is one representative experiment out of two repetitions. C) Recombinant rat TRAP enzyme activity inhibition after incubationwith various concentrations of heparan sulfate. The
graph is formed by mean values of three independent experiments. D) 3T3-L1 pre-adipocytes incubated with recombinant human TRAP 5amedia at 4 °C and 37 °C, stained (from left to
right) with mouse anti-human glypican-4 (green) and rabbit anti-rat total TRAP (red). Co-localization coefﬁcient as Pearson's global correlation (average of ﬁve images) M1 = overlap
coefﬁcient for glypican-4 andM2 = overlap coefﬁcient for TRAP. Arrow inmerged picture at 4 °C points at co-localization of TRAP 5a and glypican-4 in protrusions of the cell membrane.
Arrows in merged picture at 37 °C point at co-localization of TRAP 5a and glypican-4 in endocytosed vesicles in the cell cytoplasm. The scale bar on all immunocytochemistry images is
10 μm.
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showed a strong overlap (Pearson's coefﬁcient 0.67, M1 = 0.6 and
M2 = 0.843; Fig. 5A) between TRAP 5a and Rab-7. Moreover, electron
microscopy analysis showed that several of the vesicles where TRAP
5a was located had the morphological characteristics of multi-
vesicular bodies (MVBs) (Fig. 5B; left and middle image) [33] while onuntreated cells, there was no detectable TRAP staining (Fig. 5B; right
image). On the other hand, no co-localization of TRAP 5a with the
lysosomal marker LAMP-1 could be observed (Pearson's coefﬁcient
−0.0158, M1 = −0.297 and M2 = 0.03; Fig. 5C–D).
No staining was observed in cells in the absence of primary or sec-
ondary antibodies or cells only stained with Hoechst (Supplementary
502 C. Patlaka et al. / Biochimica et Biophysica Acta 1843 (2014) 495–507Fig. 3S). Additionally in order to evaluate that the TRAP stainingwas not
due to cross-reactivity of the TRAP antibodies, untreated 3T3-L1 pre-
adipocytes were stained for both TRAP and Rab-7/LAMP-1. No TRAP
staining was observed in these controls (Supplementary Fig. 4S).
3.6. TRAP 5a binds to pre-osteoblasts but not to MSCs and ﬁbroblasts
MSCs are precursors to pre-adipocytes thus it was investigated
whether MSCs as well as other cell types derived from MSCs such as
pre-osteoblasts and ﬁbroblasts could endocytose TRAP 5a in a manner
similar to pre-adipocytes. When the embryonic mesenchymal stem
cell line, C3H10 T1/2 or 3T3-NIH ﬁbroblasts were treated with recombi-
nant human his-TRAP 5a at 37 °C, no endocytosed TRAP 5a was detect-
able in their cytoplasm (Fig. 6; upper andmiddle panel). However, 3T3-
E1 clone 14 pre-osteoblasts were shown to endocytose recombinant
human his-TRAP 5a (Fig. 6; lower panel arrows) and their endocytosis
was shown to be caveolae-mediated as for pre-adipocytes (Supplemen-
tary Fig. 5S).
4. Discussion
Studies have shown that TRAP 5a stimulates mouse adipogenesis
in vivo [4] and that human obesity is associated with elevated blood
and adipose extracellular matrix levels of TRAP [12]. However, the
molecular events behind induction of adipogenesis by TRAP 5a remain
to be elucidated. Since binding, endocytosis and intracellular fate of
ligands affect their signaling [34], the aim of this studywas to character-
ize and assess the routes of exogenous TRAP 5a binding and uptake in
pre-adipocytes and the binding and uptake potential by other cells of
the mesenchymal lineage.
Investigation of TRAP 5a binding to pre-adipocytic membrane, using
confocal and electron microscopy, revealed that TRAP 5a binds to the
membrane in a patch-like pattern. Such binding of ligands to mem-
branes is an indication of receptor clustering and has been reported to
be the determining factor for the triggering of certain membrane pro-
teins with ligand binding capacity [35]. On the other hand, TRAP 5b
staining was undetectable on pre-adipocytic plasma membranes, sug-
gesting that the repressive peptide loop domain [36] present in TRAP
5a, but not TRAP 5b, might be involved in or required for TRAP binding
to pre-adipocytes. Binding of TRAP to pre-adipocytes is in line with a
previous report demonstrating osteoblast binding of TRAP frommacro-
phage-conditioned media [17] although this study did not distinguish
between the TRAP isoforms. However, macrophages are known to
secrete TRAP 5a, but not TRAP 5b [4,13], thus indicating that also pre-
osteoblasts bind TRAP 5a. Furthermore, TRAP 5a is suggested to be the
extracellular TRAP isoform found in adipose tissue, since the adipose tis-
sue source of TRAP ismacrophages [4,12] and TRAP isoform5a is detect-
ed in adipose tissue secretions while TRAP 5b is undetectable [12].
Consistentwith secretion of TRAP 5a frommacrophages andmembrane
binding of TRAP 5a, but not 5b, to pre-adipocytes is also the fact that
increased adipocyte proliferation and differentiation in vitro have
been demonstrated after treatment with TRAP 5a, but not TRAP 5b [4].
This further indicates that stimulation of cellular events in pre-
adipocytes is mediated through cell binding of TRAP 5a. Experiments
using a mixed population of pre-adipocytes and differentiated lipid-
laden adipocytes revealed that the capacity for TRAP 5a membrane
binding and endocytosis seems to be lost during transition from pre-Fig. 4. The endocytosis route of TRAP by pre-adipocytes is dynamin and caveolaemediated. A) T
100 nM recombinant human his-TRAP 5a ± dynamin inhibitor Dynasore. Arrows in middle p
TRAP of 3T3-L1 pre-adipocytes treated with 100 nM recombinant human his-TRAP 5a ± clat
TRAP 5a staining using mouse anti-human TRAP 5a (green) and clathrin using rabbit anti-hu
TRAP 5a media. Co-localization coefﬁcient as Pearson's global correlation (average of ﬁve
D) TRAP 5a staining (red) using rabbit anti-rat total TRAP of 3 T3-L1 pre-adipocytes treated w
picture TRAP5a + 500 μM GS point at unstained cytoplasm. E) Co-localization of TRAP 5a usin
pre-adipocytes treated with 100 nM recombinant human TRAP 5a media. Co-localization coe
for TRAP and M2= overlap coefﬁcient for caveolin-1. The scale bar on all images is 10 μm.adipocytes to mature adipocytes, possibly due to down-regulation of
membrane-bound TRAP 5a-interacting proteins (i.e. a TRAP 5a receptor
or co-receptor) during differentiation. This suggests that TRAP 5a affects
mainly proliferative stages of adipocyte differentiation and might
provide an explanation as to why the obese TRAP transgenic mouse
display increased proliferation and differentiation of pre-adipocytes
with no discernible effects on lipogenesis and lipolysis in mature adipo-
cytes [4].
Analyses of binding and endocytosis kinetics of TRAP 5a in pre-
adipocytes revealed that TRAP 5a binds and is endocytosed in a
concentration-dependent and saturable fashion. Measuring TRAP
enzyme activity, osteoblasts have previously been demonstrated to
display a concentration-dependent endocytosis of TRAP, however, this
endocytosis did not follow a sigmoidal ﬁt and did not seem to become
saturated [20]. These differences are likely to be a result of the differ-
ence in techniques used to measure TRAP. In the current study, TRAP
was measured using anti-total TRAP antibodies in combination with
FACS analysis, thus only measuring TRAP protein whereas, in the previ-
ous study [20], TRAPwasmeasured by its enzyme activity, which due to
various experimental conditions may not necessarily correlate to the
amount of TRAP protein.
Several growth factors, such as ﬁbroblast growth factor 2 (FGF2)
exhibit high afﬁnity for heparan sulfate which is essential for FGF2
signaling efﬁciency in the target cell [12,37,38]. Heparan sulfate facili-
tates the dimerization of FGF2 receptors upon FGF2 ligand binding
[39]. TRAP exhibits high afﬁnity for heparin [2,3,40] suggesting that
TRAP could also bind to HS-containing compounds in the membrane
or ECM, i.e. HS-containingmembrane bound proteoglycans or ECMpro-
teoglycans, in a manner similar to other HS-binding growth factors. Gel
ﬁltration chromatography of TRAP 5a with heparin and heparan sulfate
in this study demonstrated complex formation of TRAP 5a to heparin
thus conﬁrming previous studies [1,2,40] as well as to heparan sulfate.
Interestingly, when investigating the effect of heparin-TRAP and HS-
TRAP complex formation on TRAP phosphatase activity, it was revealed
that phosphatase activity of TRAP 5awhen in complexwith heparinwas
inhibited by around 20–40% which is in line with what has previously
been reported [1]. Conversely, TRAP 5a enzyme activity was not
inhibited in TRAP 5a/HS complex. This observation could be due to
different afﬁnities to the protein as seen for other proteins where inhi-
bition occurring by binding could have speciﬁc structural requirements
for GAGs [41].
Heparan sulfate in tissues is part of membrane-bound or ECM
proteoglycans where the former has been reported to be important
for the uptake of growth factor molecules [31]. Previous studies have
shown that the membrane bound proteoglycan glypican-4 might be
a potential binding partner for TRAP in bone [18]. Interestingly, co-
localization studies of membrane bound TRAP 5a showed co-
localization with glypican-4 especially in cell protrusions. Such co-
localization of growth factor receptors in protrusions and integrins
is not uncommon to have an effect on signal transduction [42]. Further,
endocytosed TRAP 5a and glypican-4 in pre-adipocytes showed the
presence of TRAP 5a+/glypican-4+ intracellular vesicles and a smaller
fraction of TRAP 5a−/glypican-4+ vesicles, while TRAP 5a+/glypican-
4-vesicles were undetectable. This might be an indication of a potential
interaction between TRAP 5a and glypican-4 in the membrane which
could facilitate TRAP 5a binding to pre-adipocyte membrane. However,
in order to induce signal transduction, it is likely that TRAP 5a also bindsRAP 5a staining (red) using rabbit anti-rat total TRAP of 3T3-L1 pre-adipocytes treatedwith
icture points at unstained cytoplasm. B) TRAP 5a staining (red) using rabbit anti-rat total
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Fig. 5. Endocytosed TRAP 5a co-localizes with Rab-7, is found in multi-vesicular bodies but is not co-localized with LAMP-1. A) Co-localization of TRAP staining using rabbit anti-rat total
TRAP (red) and mouse anti-human Rab-7 (green) in 3T3-L1 pre-adipocytes treated with 100 nM recombinant human TRAP 5a media and co-localization coefﬁcient as Pearson's global
correlation (average of ﬁve images) M1 = overlap coefﬁcient for Rab-7 and M2 = overlap coefﬁcient for TRAP. B) 3T3-L1 pre-adipocytes incubated with 100 nM recombinant human
TRAP 5a media or untreated at 37 °C and detected by electron microscopy C) Co-localization of TRAP staining using rabbit anti-rat total TRAP (red) and LAMP-1 using rat anti-mouse
LAMP-1(green) in 3T3-L1 pre-adipocytes treated with recombinant human TRAP 5amedia and co-localization coefﬁcient as Pearson's global correlation (average of ﬁve images)
M1 = overlap coefﬁcient for LAMP-1 and M2 = overlap coefﬁcient for TRAP. The scale bar on images A and C is 10 μm. The scale bar in image B is 200 nm. MVB = multi vesic-
ular bodies, V = vesicles, CM = cell membrane.
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glypican-4 is a GPI anchoredmolecule which is unlikely to induce signal
transduction [43].
The endocytic route of growth factors has been shown to have an
impact on the intracellular fate and the induction of signal transduction
[32,34,44], therefore characterization of the endocytic route of ligands is
important. Investigation of TRAP 5a endocytosis showed presence of
TRAP in intracellular vesicles. Further, it was shown, using the dynamin
inhibitor Dynasore [27], that TRAP 5a endocytosis is dependent on
dynamin i.e. clathrin-dependent or caveolae-mediated [45,46]. Inhibi-
tion of each of these pathways byMonodansylcadaverine andGenistein,
respectively indicated that TRAP 5a endocytosis is caveolae-mediated.
These ﬁndings were further supported by low co-localization of TRAP5a and clathrin and the partial co-localization of TRAP 5a with
caveolin-1 in pre-adipocytes. The fact that co-localization of TRAP 5a
with caveolin-1 was only partial may be a result of loss of caveolin-1
further down in the endocytic pathway [34]. Most growth factors
seem to act through clathrin-dependent endocytosis, although there
have been reports also of caveolae-mediated growth factor endocytosis
[47]. Further, it has also been suggested that endocytosis pathways of
growth factors can be differentially used by the cell depending on the
concentration of the ligand. For instance, epithelial growth factor
(EGF) endocytosis is clathrin-dependent at low ligand concentrations
but caveolae-mediated at high ligand concentration for signal down-
regulation [48]. 100 nM of TRAP 5a, which is used in the current
study, is a rather high ligand concentration; therefore, the probability
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Fig. 6. TRAP 5a binds to pre-osteoblasts but not tomesenchymal stem cells or ﬁbroblast. A) Embryonic mesenchymal stem cells (C3H10 T1/2) treatedwith serum freemedia (control; left
image) or serum freemedia containing 100 nM recombinant his-TRAP 5a (right image) followed by stainingwith rabbit anti-rat total-TRAP (green). B) Fibroblasts (NIH-3T3) treatedwith
serum freemedia (control; left image) or serum freemedia containing 100nM recombinant his-TRAP 5a (right image) followed by stainingwith rabbit anti-rat total-TRAP (green). C) Pre-
osteoblasts (3T3-E1 clone 14) treated with serum free media (control; left image) or serum free media containing 100 nM recombinant his-TRAP 5a (right image) followed by staining
with rabbit anti-rat total-TRAP (green). The scale bar in all images corresponds to 200 μm.
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radation and down regulation of TRAP 5a induced signal transduction
is likely.
Once endocytosed by pre-adipocytes, TRAP 5a co-localizes with the
late endosome marker Rab-7. Further down the endocytic pathway,
TRAP 5awas shown to be present in vesicles whosemorphology resem-
blesMVB using electronmicroscopy. Interestingly, TRAP 5a does not co-
localize with lysosomal marker LAMP-1 which could indicate that, if
endocytosed, exogenous TRAP 5a reaches the lysosomes where it
becomes degraded and not detectable by the antibodies used in this
study. Previous studies have examined the intracellular localization of
endogenously expressed TRAP in osteoblasts andmacrophages. In oste-
oblasts, endogenously expressed TRAP is found in the Golgi complex
and lysosomes [22] and in macrophages it has been localized to late,
but not early, endosomes, lysosomes aswell as to large vesicles contain-
ing MHC II and phagocytosed material [23,49]. Together, these dataindicate that there are different routes for endogenously expressed
TRAP and endocytosed exogenous TRAP. Endogenous TRAP seems to
go through the Golgi complex and is then sorted to and stored in lyso-
someswhich latermay fusewith phagosomes. Here TRAP can potential-
ly participate in clearance of phagocytosed material [50,51]. On the
other hand, endocytosed exogenous TRAP 5a transits to late endosomes
possibly through MVB and possibly ends up in lysosomes in order to be
degraded and not utilized for lysosomal activities.
Adipocytes are differentiated from mesenchymal stem cells (MSCs)
that can also be differentiated into e.g. ﬁbroblasts, chondrocytes and
osteoblasts [52]. Additionally, it has been shown that there is plasticity
between the osteogenic and adipogenic lineage [53] indicating a close
relationship between these cell types. Presence of TRAP 5a in endocytic
vesicles in cells of MCS lineages after TRAP 5a treatment was evident in
pre-adipocytes and pre-osteoblasts. This is in line with previous studies
showing TRAP binding, endocytosis or TRAP-mediated effects in these
506 C. Patlaka et al. / Biochimica et Biophysica Acta 1843 (2014) 495–507cell types [4,5,17,20]. On the other hand, TRAP 5a could not be detected
in embryonic MCSs or ﬁbroblasts after TRAP 5a treatment. However,
earlier studies have shown that treatment of human MSCs derived
from adipose tissue with TRAP 5a enhances proliferation and differenti-
ation of these cells [4] and gingival ﬁbroblasts cultured with macro-
phage conditioned media containing TRAP have been shown to have
elevated intracellular levels of TRAP [17]. These discrepancies between
the current and previous studies of TRAP effect and endocytosis in
MSC and ﬁbroblasts might reﬂect differences in sources of cell lines.
The embryonic MSCs C3H10T1/2 used in the current study might be
less differentiated than the MSCs derived from human adipose tissue
[4] and maturation between NIH-3T3 used in the current study and
gingival ﬁbroblast [20] might also differ. Additionally, this study aimed
at identifying the interaction between TRAP and well-established cell
lines such as the pre-adipocyte cell line 3T3-L1, but it still remains to be
elucidated if TRAP interacts in a similar manner in primary cells derived
from adipose tissue and other sources of mesenchymal lineage cells.
In summary, TRAP 5a, but likely not 5b, binds to pre-adipocytic but
not mature lipid containing adipocytic membranes in a concentration-
dependent and saturable fashion. Membrane binding of TRAP 5a
appears to be mediated via complex formation with heparan sulfate
containing membrane bound proteoglycans where one candidate for
such an interaction is glypican-4. At high concentrations, TRAP 5a was
endocytosed in a caveolae-mediated manner and later found in late
endosomes and MVB but not in lysosomes, possibly due to TRAP 5a
degradation. Among other MSC-derived cells also pre-osteoblasts, but
not ﬁbroblasts or embryonic mesenchymal stem cells bind and
endocytose TRAP 5a in a caveolae-mediated manner.
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